|
- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca We’ve brought the Cafepharma Job Board back If you’re hiring—or looking— check out the latest listings
- AstraZeneca | Cafepharma
AstraZeneca is pouring $136 million more into the expansion of an inhalants production base in China The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million AstraZeneca unveiled (Chinese) the outlay Wednesday at the China International Import Expo (CIIE), an annual event where foreign companies parade their commitments to the country
- November 6 2025 - With 2030 ambitions in view, AstraZeneca’s quarterly . . .
With 2030 ambitions in view, AstraZeneca’s quarterly revenue passes $15B for first timeAstraZeneca boardEli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3Eli Lilly boardNovartis’ Pluvicto heavywork proves radiopharma can succeedNovartis boardJ J adds first new indication for Caplyta since takeover
- AstraZeneca | Cafepharma
AstraZeneca broke ground today on a massive manufacturing complex near Charlottesville, Virginia, its largest facility worldwide and a cornerstone of the company’s $50 billion U S R D and manufacturing plan through 2030 The company intends to ramp up investment and scope of the facility to $4 5 billion, which would eventually create 3,600 new jobs as the site expands
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- Fasenra | Cafepharma
AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic phenotype A phase III clinical trial is now underway to test the effectiveness of Fasenra in COPD
- AstraZenecas Fasenra (benralizumab) Fails Ph III Trial for COPD
AstraZeneca and MedImmune, announced on 5 11 18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD
- Pharma Biotech Companies | Cafepharma Message Boards | Pharma Sales . . .
Pharma Biotech Comp - Gen Discussion |Pharma Sales New Anonymous general discussion board for pharma biotech companies 448 7 3K Threads 448 Messages 7 3K Driving Record Background chec Friday at 10:52 PM anonymous 123
|
|
|